MediciNova , Phase IIa Clinical Study Results for MN-305, a Treatment for Insomnia

Oct 18, 2007 - MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), announced results from a Phase IIa clinical study of MN-305, its product candidate for the treatment of insomnia. The clinical study failed to achieve statistical significance in its primary endpoint of reducing Wake (time) After Sleep Onset (WASO). MN-305 was well tolerated in this study with no clinically significant adverse events observed at any dose tested... MediciNova's Press Release-

Immtech , Interim Analysis in Phase III African Sleeping Sickness Trial

Thursday October 4, 2007 - Immtech Pharmaceuticals, Inc. (Amex: IMM) announced the completion of interim analysis of its Phase III pivotal clinical trial of Immtech's oral drug candidate, pafuramidine. An independent Data Safety Monitoring Board (DSMB) conducted the interim analysis and recommended that the trial should continue as planned. The trial is evaluating the safety and tolerability of pafuramidine, and comparing pafuramidine's efficacy to pentamidine, a non-oral drug, in treating Human African Tryanosomiasis (HAT), also know as African sleeping sickness*... Immtech's Press Release [PDF]-

Upstream Biosciences, New Approach to Treating Sleeping Sickness

October 2, 2007 - Upstream Biosciences Inc. (OTCBB: UPBS) announced that its Chief Executive Officer, Joel L. Bellenson, will unveil Upstream's promising new drug candidates in a keynote address to the International Scientific Council for Trypanosomiasis Research and Control (ISCTRC) conference being held in Angola from October 1 to 5, 2007... Trypanosomiasis is the medical term for the disease known as African sleeping sickness.... Upstream recently acquired access to innovative drug candidates designed to treat tropical parasitic diseases. In laboratory studies in vitro, these compounds have demonstrated human and veterinary potential against several major tropical parasitic diseases, including trypanosomiasis... Upstream Biosciences' Press Release -

Transcept Pharmaceuticals, Middle-of-the-Night (MOTN) Insomnia

October 1, 2007: Transcept Pharmaceuticals, Inc. announced that Glenn A. Oclassen, President and Chief Executive Officer, will participate in a panel focused on middle-of-the-night (MOTN) insomnia ( form of insomnia that is characterized by patients who awaken in the middle of the night and have difficulty returning to sleep) at the Natixis Bleichroeder “Hidden Gems” Healthcare Conference... Transcept's Press Release -